Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Discovery of the transcription factor ZNF683/hobit as a central regulator of pathogenic T cell proliferation in acute gvhd

Alexandre Albanese, Edward Chen, Yvonne Suessmuth, Jiayi Dong, James Kaminski, Lev Gorfinkel, Ally Eran, Jillian Zavistaski, Lorenzo Cagnin, Paul Keskula, Brandi Bratrude, Kayla Betz, Elham Rayzan, Muna Qayed, John Horan, Amelia Langston, Benjamin Watkins, Bruce Blazar, Leslie Kean

Blood (2025) 146 (Supplement 1): 275.

https://doi.org/10.1182/blood-2025-275

Published: 2025

Journal Articles

T cell receptor costimulation blockade effectively prevents acute graft versus host disease without reducing the size or diversity of the T cell immune repertoire

Chiara Wychera, Alexandre Albanese, Steven Siegel, Joseph Schmalz, Stephanie Bien, Brandi Bratrude, Kayla Betz, Lev Gorfinkel, Lorenzo Cagnin, Paul Keskula, Bruce Blazar, Muna Qayed, John Horan, Amelia Langston, Benjamin Watkins, Leslie Kean

Blood (2025) 146 (Supplement 1): 819.

https://doi.org/10.1182/blood-2025-819

Published: 2025

Journal Articles

Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2‘)

Blood (2024) 144 (Supplement 1): 3516.

https://doi.org/10.1182/blood-2024-205130

Published: 2024

Journal Articles

Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation

Leslie S. Kean, Linda J. Burns, Tzuyung D. Kou, Roxanne Kapikian, Karissa Lozenski, Amelia Langston, John T. Horan, Benjamin Watkins, Muna Qayed, Brandi Bratrude, Kayla Betz, Xiao-Ying Tang, Mei-Jie Zhang, Sean E. Connolly, Martin Polinsky, Brian Gavin, Andres Gomez-Caminero, Marcelo C. Pasquini

Blood (2024) 144 (17): 1834–1845.

https://doi.org/10.1182/blood.2023023660

Published: 2024

Includes: Supplemental data

Journal Articles

Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events

Blood (2023) 142 (8): 700–710.

https://doi.org/10.1182/blood.2023020035

Published: 2023

Includes: Supplemental data

Journal Articles

Abatacept for the Prevention of Gvhd in Pediatric and Adult Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis

Sharmila Raghunandan, Lev Gorfinkel, Michael Graiser, Brandi Bratrude, Kayla Betz, Yvonne Suessmuth, Scott Gillespie, Adrianna Lynn Westbrook, Kirsten M. Williams, Michelle Schoettler, Amelia Langston, Leslie Kean, Muna Qayed, John T. Horan, Benjamin Watkins

Blood (2022) 140 (Supplement 1): 7653–7655.

https://doi.org/10.1182/blood-2022-163627

Published: 2022

Journal Articles

Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial

Alexandre Albanese, Alal Eran, Yvonne Suessmuth, Kayla Betz, Brandi Bratrude, Paula Keskula, Lorenzo Cagnin, Amelia Langston, Muna Qayed, John T. Horan, Bruce R. Blazar, Benjamin Watkins, Leslie S. Kean

Blood (2022) 140 (Supplement 1): 274–275.

https://doi.org/10.1182/blood-2022-170693

Published: 2022

Journal Articles

MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Blood (2021) 138 (Supplement 1): 2955.

https://doi.org/10.1182/blood-2021-149313

Published: 2021

Journal Articles

Predicting Immune Pathology after Hematopoietic Stem Cell Transplant with Transcriptomics: Naïve CD4 T Cell Expansion at Day 100 Predicts Patients with De Novo Chronic Gvhd

Ben Watkins, MD, James Kaminski, Muna Qayed, MDMSc, Kayla Betz, BS, Yvonne Suessmuth, PhD, Brandi Bratrude, Alison Yu, PhD, Victor Tkachev, PhD, Kathryn Pellegrini, Steven Bosinger, PhD, Bruce R. Blazar, MD, John T. Horan, MDMPH, Amelia Langston, MD, Leslie Kean, MD PhD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-139488

Published: 2020

Journal Articles

Potent Interaction between CMV Reactivation and Gvhd: Immunologic Evidence for Blunting of CMV-Driven Immune Reconstitution in the Setting of Gvhd

Yvonne Suessmuth, PhD, Kayla Betz, BS, Alison Yu, PhD, Brandi Bratrude, Benjamin Watkins, MD, Muna Qayed, MDMSc, John T. Horan, MDMPH, Leslie Kean, MD PhD, Amelia Langston, MD

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-141856

Published: 2020

Journal Articles

Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept

Benjamin Watkins, Yvonne Suessmuth, Kayla Betz, BS, Alison Yu, PhD, Brandi Bratrude, Muna Qayed, MD MSc, Kathryn Pellegrini, Steven Bosinger, Amelia Langston, MD, John T. Horan, MDMPH, Bruce R. Blazar, MD, Leslie Kean, MD PhD

Blood (2019) 134 (Supplement_1): 596.

https://doi.org/10.1182/blood-2019-131955

Published: 2019

Journal Articles

T Cell Costimulation Blockade with Abatacept Nearly Eliminates Early Severe Acute Graft Versus Host Disease after HLA-Mismatched (7/8 HLA Matched) Unrelated Donor Transplant, with a Favorable Impact on Disease-Free and Overall Survival

Blood (2017) 130 (Supplement 1): 212.

https://doi.org/10.1182/blood.V130.Suppl_1.212.212

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Discovery of the transcription factor ZNF683/hobit as a central regulator of pathogenic T cell proliferation in acute gvhd

T cell receptor costimulation blockade effectively prevents acute graft versus host disease without reducing the size or diversity of the T cell immune repertoire

Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2‘)

Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation

Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events

Abatacept for the Prevention of Gvhd in Pediatric and Adult Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis

Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial

MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Predicting Immune Pathology after Hematopoietic Stem Cell Transplant with Transcriptomics: Naïve CD4 T Cell Expansion at Day 100 Predicts Patients with De Novo Chronic Gvhd

Potent Interaction between CMV Reactivation and Gvhd: Immunologic Evidence for Blunting of CMV-Driven Immune Reconstitution in the Setting of Gvhd

Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept

T Cell Costimulation Blockade with Abatacept Nearly Eliminates Early Severe Acute Graft Versus Host Disease after HLA-Mismatched (7/8 HLA Matched) Unrelated Donor Transplant, with a Favorable Impact on Disease-Free and Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only